Mendus AB (publ) (IMMU.ST)
SEK 8.51
(-1.06%)
SEK 8.51
(-1.06%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -100.65 Million SEK | 24.71% |
| 2022 | -133.68 Million SEK | -2.75% |
| 2021 | -130.1 Million SEK | -51.23% |
| 2020 | -86.02 Million SEK | 34.99% |
| 2019 | -132.32 Million SEK | -35.24% |
| 2018 | -97.84 Million SEK | -21.25% |
| 2017 | -80.69 Million SEK | -9.83% |
| 2016 | -73.47 Million SEK | -68.35% |
| 2015 | -43.64 Million SEK | -19.89% |
| 2014 | -36.4 Million SEK | -118.62% |
| 2013 | -16.65 Million SEK | -138.8% |
| 2012 | -6.97 Million SEK | -158.86% |
| 2011 | -2.69 Million SEK | 0.75% |
| 2010 | -2.71 Million SEK | -17.44% |
| 2009 | -2.31 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -38 Million SEK | 18.28% |
| 2024 Q2 | -38.27 Million SEK | 0.16% |
| 2023 Q3 | -25.85 Million SEK | 6.79% |
| 2023 Q4 | -46.5 Million SEK | -79.86% |
| 2023 Q2 | -27.73 Million SEK | 6.32% |
| 2023 FY | -129.7 Million SEK | 2.98% |
| 2023 Q1 | -29.6 Million SEK | 28.36% |
| 2022 Q2 | -28.13 Million SEK | -4.9% |
| 2022 Q3 | -37.4 Million SEK | -32.95% |
| 2022 FY | -133.68 Million SEK | -2.75% |
| 2022 Q4 | -41.32 Million SEK | -10.49% |
| 2022 Q1 | -26.82 Million SEK | 15.52% |
| 2021 Q2 | -31.27 Million SEK | 23.3% |
| 2021 Q1 | -40.78 Million SEK | -661.39% |
| 2021 FY | -130.1 Million SEK | -51.23% |
| 2021 Q4 | -31.74 Million SEK | -20.72% |
| 2021 Q3 | -26.29 Million SEK | 15.92% |
| 2020 Q3 | -21.65 Million SEK | 13.92% |
| 2020 Q1 | -33.86 Million SEK | 16.02% |
| 2020 FY | -86.02 Million SEK | 34.99% |
| 2020 Q4 | -5.35 Million SEK | 75.26% |
| 2020 Q2 | -25.15 Million SEK | 25.74% |
| 2019 Q4 | -40.33 Million SEK | -36.06% |
| 2019 Q1 | -29.13 Million SEK | -11.18% |
| 2019 Q2 | -33.21 Million SEK | -13.97% |
| 2019 Q3 | -29.64 Million SEK | 10.74% |
| 2019 FY | -132.32 Million SEK | -35.24% |
| 2018 Q2 | -19.34 Million SEK | 32.75% |
| 2018 FY | -97.84 Million SEK | -21.25% |
| 2018 Q1 | -28.77 Million SEK | -47.88% |
| 2018 Q4 | -26.2 Million SEK | -11.43% |
| 2018 Q3 | -23.52 Million SEK | -21.56% |
| 2017 Q3 | -21.59 Million SEK | -12.99% |
| 2017 Q1 | -20.53 Million SEK | 16.93% |
| 2017 FY | -80.69 Million SEK | -9.83% |
| 2017 Q4 | -19.45 Million SEK | 9.92% |
| 2017 Q2 | -19.11 Million SEK | 6.9% |
| 2016 Q1 | -9.52 Million SEK | 15.13% |
| 2016 FY | -73.47 Million SEK | -68.35% |
| 2016 Q4 | -24.71 Million SEK | -105.67% |
| 2016 Q3 | -12.01 Million SEK | 20.24% |
| 2016 Q2 | -15.06 Million SEK | -58.14% |
| 2015 Q4 | -11.22 Million SEK | -43.57% |
| 2015 Q1 | -10.65 Million SEK | 4.23% |
| 2015 Q2 | -8.23 Million SEK | 22.78% |
| 2015 Q3 | -7.81 Million SEK | 4.99% |
| 2015 FY | -43.64 Million SEK | -19.89% |
| 2014 Q1 | -5.01 Million SEK | -27.68% |
| 2014 FY | -36.4 Million SEK | -118.62% |
| 2014 Q4 | -11.12 Million SEK | -74.22% |
| 2014 Q3 | -6.38 Million SEK | -9.35% |
| 2014 Q2 | -5.84 Million SEK | -16.47% |
| 2013 Q3 | -1.86 Million SEK | 33.13% |
| 2013 FY | -16.65 Million SEK | -138.8% |
| 2013 Q2 | -2.79 Million SEK | -8.55% |
| 2013 Q1 | -2.57 Million SEK | -134.35% |
| 2013 Q4 | -3.92 Million SEK | -110.31% |
| 2012 Q4 | -1.09 Million SEK | 0.0% |
| 2012 Q3 | -1.09 Million SEK | 32.05% |
| 2012 Q2 | -1.61 Million SEK | 0.0% |
| 2012 Q1 | -1.61 Million SEK | 0.0% |
| 2012 FY | -6.97 Million SEK | -158.86% |
| 2011 FY | -2.69 Million SEK | 0.75% |
| 2010 FY | -2.71 Million SEK | -17.44% |
| 2009 FY | -2.31 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 59.576% |
| Ziccum AB (publ) | -21.56 Million SEK | -366.837% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -513.682% |
| BioArctic AB (publ) | 252.64 Million SEK | 139.839% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -11811.243% |
| Genovis AB (publ.) | 54.22 Million SEK | 285.619% |
| Intervacc AB (publ) | -93.57 Million SEK | -7.556% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -548.853% |
| Active Biotech AB (publ) | -46.48 Million SEK | -116.526% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 658.887% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -81.623% |
| Aptahem AB (publ) | -10.1 Million SEK | -896.065% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 68.694% |
| Kancera AB (publ) | -65.04 Million SEK | -54.746% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 25.232% |
| Fluicell AB (publ) | -26.87 Million SEK | -274.456% |
| Saniona AB (publ) | -81.06 Million SEK | -24.16% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -713.596% |
| Biovica International AB (publ) | -126.07 Million SEK | 20.165% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -136.796% |
| AcouSort AB (publ) | -17.48 Million SEK | -475.57% |
| Xintela AB (publ) | -57.23 Million SEK | -75.845% |
| Abliva AB (publ) | -96.54 Million SEK | -4.249% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 69.012% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -2771.612% |
| OncoZenge AB (publ) | -15.9 Million SEK | -532.939% |
| Amniotics AB (publ) | -29.07 Million SEK | -246.198% |
| 2cureX AB (publ) | -36.36 Million SEK | -176.792% |
| CombiGene AB (publ) | -36.3 Million SEK | -177.233% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -587.5% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 73.816% |
| Camurus AB (publ) | 532.35 Million SEK | 118.907% |
| Corline Biomedical AB | -1.78 Million SEK | -5529.195% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 44.32% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -141.465% |
| I-Tech AB | 24.43 Million SEK | 511.909% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 87.235% |
| Cyxone AB (publ) | -21.66 Million SEK | -364.66% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 5.016% |
| Biosergen AB | -27.26 Million SEK | -269.155% |
| Cantargia AB (publ) | -290.01 Million SEK | 65.295% |
| NextCell Pharma AB | -43.17 Million SEK | -133.137% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 44.32% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -488.725% |
| Nanologica AB (publ) | -69.96 Million SEK | -43.862% |
| SynAct Pharma AB | -224.49 Million SEK | 55.166% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -127.839% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -320.176% |
| LIDDS AB (publ) | -40.67 Million SEK | -147.455% |
| Lipum AB (publ) | -37.25 Million SEK | -170.172% |
| BioInvent International AB (publ) | -369.94 Million SEK | 72.793% |
| Alzinova AB (publ) | -16.52 Million SEK | -509.188% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 60.288% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -1474.317% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 12.534% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -399.777% |
| Simris Alg AB (publ) | -36.63 Million SEK | -174.737% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 31.328% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 67.577% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 9.254% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -770.223% |